

Special Issue

Research on Fluorescence-Guided Surgery in Cancer Treatment

Message from the Guest Editor

Fluorescence-guided surgery (FGS) is a novel technique that uses fluorescent agents to enhance the visualization of tumor margins and residual tumor cells during surgery. FGS has been shown to improve the extent of resection and the accuracy of biopsy in various types of cancers, such as gliomas, metastases, lymphomas, meningiomas, and others. However, FGS also faces some challenges, such as the limited availability of approved fluorescent agents, the variability of tumor fluorescence, the interference of background fluorescence, and the need for specialized equipment and training. This Special Issue aims to provide an overview of the current state of the art and the future perspectives of FGS in cancer treatment. We encourage you to consider submitting an article for this Special Issue. Our goal is to provide a forum for the exchange of ideas and knowledge and to promote the advancement of neurosurgery. We welcome original research articles and review articles that contribute to our understanding of these exciting developments. Please contact us for more information and to submit your article.

Guest Editor

Dr. Julius Höhne

Department of Neurosurgery, Paracelsus Medical University,
Nuremberg, Germany

Deadline for manuscript submissions

closed (30 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/197266

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)